Splisense Company

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
Technology: Gene Therapy
Industry: Geroscience
Headquarters: Jerusalem, Yerushalayim, Israel
Founded Date: 2016-01-01
Employees Number: 1-10
Funding Status: Seed
Investors Number: 5
Total Funding: 28500000
Last Funding Date: 2021-05-13
Last Funding Type: Series B

Visit Website
liana@integra-holdings.com
https://splisense.com/
Register and Claim Ownership